UK breast cancer patients win early access to Tecentriq/nab-paclitaxel

14th March 2019 Uncategorised 0

Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) have won early access to Roche’s immunotherapy Tecentriq in combination with nab-paclitaxel chemotherapy.

More: UK breast cancer patients win early access to Tecentriq/nab-paclitaxel
Source: News